Abbott Laboratories (NYSE:ABT) Stock Position Raised by Quantinno Capital Management LP

Quantinno Capital Management LP raised its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 87.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 232,665 shares of the healthcare product maker's stock after acquiring an additional 108,621 shares during the quarter. Quantinno Capital Management LP's holdings in Abbott Laboratories were worth $26,317,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ABT. Redwood Park Advisors LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Noble Wealth Management PBC purchased a new stake in Abbott Laboratories during the 4th quarter worth about $26,000. NewSquare Capital LLC increased its position in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after purchasing an additional 105 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in Abbott Laboratories during the 4th quarter worth about $28,000. Finally, Rialto Wealth Management LLC purchased a new stake in Abbott Laboratories during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ABT shares. Bank of America increased their price target on Abbott Laboratories from $133.00 to $150.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Royal Bank of Canada lifted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Thursday, April 17th. The Goldman Sachs Group upped their price objective on shares of Abbott Laboratories from $138.00 to $154.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. UBS Group upped their price objective on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Finally, Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $136.00 to $147.00 and gave the company an "overweight" rating in a research note on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus target price of $142.59.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT traded up $1.44 on Friday, hitting $134.79. The company's stock had a trading volume of 7,128,620 shares, compared to its average volume of 6,120,941. The stock's 50-day moving average is $129.36 and its two-hundred day moving average is $124.03. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The company has a market capitalization of $234.51 billion, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 2.52 and a beta of 0.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th were issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.75%. The ex-dividend date was Tuesday, April 15th. Abbott Laboratories's dividend payout ratio is 30.61%.

Insider Activity

In related news, EVP Andrea F. Wainer sold 949 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $131,123.33. Following the completion of the sale, the executive vice president now directly owns 74,381 shares of the company's stock, valued at approximately $10,277,222.77. This represents a 1.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Eric Shroff sold 562 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now directly owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This represents a 1.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 95,278 shares of company stock valued at $12,745,859 over the last three months. Insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.